Canada Markets open in 4 hrs 44 mins

Ceapro Inc. (CZO.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.63000.0000 (0.00%)
At close: 3:51PM EDT

Ceapro Inc.

7824 – 51 Avenue NW
Edmonton, AB T6E 6W2
Canada

http://www.ceapro.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Gilles R. Gagnon M.B.A., M.Sc., MBA, ICD.DCEO, Pres & Director480kN/A1954
Ms. Stacy Prefontaine CPA, CACFO & Corp. Sec.195.25kN/AN/A
Dr. Bernhard SeifriedSr. Director of Research & TechnologyN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19; a research project with the University of Alberta to expand the utilization of the PGX technology and generate ingredients targeting applications in functional food, dietary supplement, personal care, and pharmaceuticals; a research collaboration with Montreal Heart Institute for clinical study evaluating avenanthramide; and a research collaboration with Angiogenesis Foundation. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.

Corporate Governance

Ceapro Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.